基本信息
views: 0
Career Trajectory
Bio
My lab is interested in elucidating the molecular and cellular mechanisms involved in tumor-mediated immune suppression and cancer immunotherapy resistance. Our overriding hypothesis is that tumor cells and/or their associated stromal elements elicit soluble factors that tolerize local dendritic cell populations and/or recruit other immunosuppressive cell populations to the tumor bed; thereby, interfering with the generation of an effective anti-tumor immune response. This work has both basic and translational significance in that it is capable of providing 1. novel pharmacological targets for enhancing anti-tumor immunity and 2. much needed biomarkers for guiding the management of cancer patients with immunotherapies. We perform these investigations utilizing both transgenic murine models as well as clinical specimens derived from cancer patients undergoing immunotherapy. We focus these studies on melanoma, non-small cell lung cancer, pancreatic cancer, and colon cancer.
We currently have the following ongoing projects in our lab:
1. Investigating mechanisms by which developing cancers alter the metabolism of local dendritic cells thereby hijacking this antigen-presenting cell population to generate an immunotolerant tumor microenvironment.
2. Identifying soluble factors expressed by cancers which manipulate local dendritic cell function to drive regulatory T cell differentiation within the tumor microenvironment as well as any potential oncogenic signaling pathways driving this process.
3. Characterizing mechanisms of innate and adaptive resistance mechanisms to checkpoint inhibitor therapies.
4. Examining the role of the tumor stroma in interfering with immunotherapy efficacy.
5. Design and development of novel dendritic cell-based vaccine strategies
We currently have the following ongoing projects in our lab:
1. Investigating mechanisms by which developing cancers alter the metabolism of local dendritic cells thereby hijacking this antigen-presenting cell population to generate an immunotolerant tumor microenvironment.
2. Identifying soluble factors expressed by cancers which manipulate local dendritic cell function to drive regulatory T cell differentiation within the tumor microenvironment as well as any potential oncogenic signaling pathways driving this process.
3. Characterizing mechanisms of innate and adaptive resistance mechanisms to checkpoint inhibitor therapies.
4. Examining the role of the tumor stroma in interfering with immunotherapy efficacy.
5. Design and development of novel dendritic cell-based vaccine strategies
Research Interests
Papers共 108 篇Author StatisticsCo-AuthorSimilar Experts
By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Science Immunologyno. 95 (2024)
biorxiv(2024)
Nagendra Yarla, Kaylee Howell,Y-Van Nguyen, Donna Niedwiecki,Hope Uronis,John Strickler,Nicholas C. DeVito,Bala Theivanthiran,Brent A. Hanks
Cancer Researchno. 6_Supplement (2024): 7521-7521
Annals of surgeryno. 6 (2023): E1306-E1312
Journal for ImmunoTherapy of Cancerno. Suppl 1 (2023)
Elle C. Moore,Gerard C. Blobe,Nicholas C. Devito,Brent A. Hanks,Michael R. Harrison,Christopher J. Hoimes,Jingquan Jia,Michael A. Morse, Parvathy Jayaprakasan, Andrew MacKelfresh,Hillary Mulder,Adam J. Hockenberry, Alia Zander,Martin C. Stumpe,Jackson Michuda,Kyle A. Beauchamp,Eric Perakslis,Timothy Taxter,Daniel J. George
April K.S. Salama,Manisha Palta,Christel Rushing, Sisi Ma, Kristen N. Linney,Brian G. Czito,David S. Yoo,Brent A. Hanks,Georgia M. Beasley,Paul J. Mosca,Chelsae Dumbauld, Katelyn N. Steadman,John S. Yi,Kent J. Weinhold,Douglas S. Tyler,Walter T. Lee,David M. Brizel
openalex(2023)
Load More
Author Statistics
#Papers: 107
#Citation: 2567
H-Index: 27
G-Index: 50
Sociability: 8
Diversity: 3
Activity: 70
Co-Author
Co-Institution
D-Core
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn